Novartis transfers Novartis Ringaskiddy in Ireland to Sterling Pharma Solutions

January 10th 2023.

Novartis confirmed today that it has finalised the transfer of Novartis Ringaskiddy to Sterling Pharma Solutions. 

Sterling was selected following an in-depth assessment process to identify the best fit for Novartis in terms of quality, services, culture and values, and to secure a sustainable future for their Ringaskiddy employees. As part of the agreement, Sterling will produce medicines in Ireland for Novartis and the move is a continuation of the site’s transformation journey to a more sustainable future. 

"We are very proud of our colleagues who have achieved an excellent reputation for high quality, reliable production over the last 27 years. The Ringaskiddy Campus will continue to play an important role in producing cardiology, immunology and oncology medicines for Novartis. Sterling has a long-term strategy to invest in the Ringaskiddy site, developing more capacity and capabilities to attract customers from across the globe.”

Media contact:
Tina Quinn 
AM O’Sullivan PR 
Mobile: +353 087 988 1890
[email protected] 

Susanne O’Reilly
Head Country Communications, Novartis Ireland        
Mobile: +353 86 224 8381                                
[email protected]